SCHEMBL29935837

SCHEMBL29935837

COc1cc(C=O)c2ccccc2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
MCL1 Q07820 1/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
POLB P06746 2/20 0.46
ERN1 O75460 2/20 0.45
ALOX15 P16050 1/20 0.43
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 3/20 0.42
HPGD P15428 2/20 0.42
NPC1 O15118 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 1/20 0.41
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
HTR3A P46098 1/20 0.41
HTR3D Q70Z44 1/20 0.41
HTR3C Q8WXA8 1/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23152002 1.00 LMNA (0.48) LMNAL3MBTL1MCL1MEN1KMT2A
SCHEMBL30251616 0.81 ALDH1A1 (0.42) LMNAL3MBTL1ERN1ALDH1A1KDM4E
SCHEMBL28910001 0.81 ALDH1A1 (0.42) LMNAL3MBTL1ERN1ALDH1A1KDM4E
SCHEMBL423891 0.79 L3MBTL1 (0.71) LMNAL3MBTL1MEN1KMT2APOLB
SCHEMBL29935705 0.77 CYP1A2 (0.63) L3MBTL1MEN1KMT2APOLBERN1
SCHEMBL1914529 0.77 CYP1A2 (0.63) L3MBTL1MEN1KMT2APOLBERN1
SCHEMBL12990293 0.77 CYP1A2 (0.40) LMNAL3MBTL1MCL1MEN1KMT2A
SCHEMBL19651360 0.77 NPC1 (0.44) LMNAMEN1KMT2APOLBERN1
SCHEMBL9361568 0.76 MAPT (0.66) LMNAMEN1KMT2APOLBALDH1A1
SCHEMBL19422787 0.76 NPC1 (0.49) LMNAL3MBTL1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-07-11 US disclosed
US-11891387-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2024-02-06 US disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-20220372030-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-11-24 US disclosed
US-20220332713-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332713-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP LMNA 1308/4885L3MBTL1 721/4885MCL1 1896/4885
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP LMNA 1185/4885L3MBTL1 403/4885MCL1 1001/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH LMNA 1988/4885L3MBTL1 1163/4885MCL1 915/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP LMNA 1308/4885L3MBTL1 721/4885MCL1 1896/4885
US-11891387-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP LMNA 1185/4885L3MBTL1 403/4885MCL1 1001/4885
US-20220372030-A1 MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP LMNA 1185/4885L3MBTL1 403/4885MCL1 1001/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP LMNA 1308/4885L3MBTL1 721/4885MCL1 1896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.